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Skin cancergulates a wide variety of cellular processes during development and it also plays a
crucial role in human diseases. This important link is ﬁrmly established in cancer, since a rare T-ALL-
associated genetic lesion has been initially reported to result in deletion of Notch1 ectodomain and
constitutive activation of its intracellular region. Interestingly, the cellular response to Notch signaling can be
extremely variable depending on the cell type and activation context. Notch signaling triggers signals
implicated in promoting carcinogenesis and autoimmune diseases, whereas it can also sustain responses that
are critical to suppress carcinogenesis and to negatively regulate immune response. However, Notch
signaling induces all these effects via an apparently simple signal transduction pathway, diversiﬁed into a
complex network along evolution from Drosophila to mammals. Indeed, an explanation of this paradox
comes from a number of evidences accumulated during the last few years, which dissected the intrinsic
canonical and non-canonical components of the Notch pathway as well as several modulatory extrinsic
signaling events. The identiﬁcation of these signals has shed light onto the mechanisms whereby Notch and
other pathways collaborate to induce a particular cellular phenotype. In this article, we review the role of
Notch signaling in cells as diverse as T lymphocytes and epithelial cells of the epidermis, with the main focus
on understanding the mechanisms of Notch versatility.
© 2008 Elsevier B.V. All rights reserved.1. Notch signaling: not only a canonical pathway
The Notch signaling pathway appears as a paradigm of simplicity.
Indeed, the core signaling relies on relatively few components to
convey the signal from the cell surface to the transcriptional
machinery. This is exempliﬁed by the Drosophila pathway in which a
single Notch receptor signals through the transcriptional regulator
Suppressor of Hairless (Su(H). In mammals, the pathway diversiﬁed
into four Notch receptors (Notch 1–4), and all of them are regulated
through a common processing mechanism. After its synthesis in the
ER, the Notch receptor is transported through the secretory pathway
to the trans-Golgi network, where it is constitutively cleaved by a
furin-like convertase [1,2]. Following this proteolytic processing event,
referred as S1 cleavage, the Notch receptor proceeds to the cell surface,
where, as a trans-membrane receptor, it can interact with ligands
presented on neighboring cells. Notch ligands are also trans-Pathology, Dipartimento di
iale Regina Elena 324, 00161
repanti).
l rights reserved.membrane proteins comprising two different sub-families, Delta and
Serrate/Jagged, each including several members [3]. Upon ligand–
receptor interaction between cells in physical contact, Notch receptors
become susceptible to cleavage by ADAM-type metalloproteases at
site S2, creating a short-lived intermediate, Notch-Trans-membrane
(N™). Two ADAMs have been implicated in the S2 cleavage of
Notch. In Drosophila, ADAM10 ortholog Kuzbanian is the main
protease mediating Notch processing [4–7] (for review see [8]). In
mouse cells in vitro, ADAM17, and not ADAM10, appears to be a
protease responsible for Notch cleavage [9,10]. ADAM17-deﬁcient
mice do not show, however, a Notch-deﬁcient-like phenotype [11].
In contrast, ADAM10 deﬁciency leads to embryonic lethality at E9.5
and multiple malformations [12] resembling those observed in
Notch1 knock-out mice, in mice homozygous for a γ-secretase
processing-deﬁcient allele of Notch1, or in presenilin1/presenilin2
double-knock-out mice [13–15]. Thus, as proposed by Hartmann
et al. [12], different ADAMs may contribute to the S2 cleavage in a
tissue-speciﬁc manner, with ADAM10 playing the major role in this
process in vivo. N™ is recognized and rapidly cleaved at site S3 by
a multiprotein protease complex known as γ-secretase, which
releases the active intracellular form of Notch, (NICD) [16,17]. Once
Fig. 1. Canonical and non-canonical Notch signaling. A diagram of Notch canonical signaling pathways is compared to the non-canonical Notch pathway. Note that the canonical
Notch pathway has been simpliﬁed to include only the main components. The interaction of ligands with Notch leads to the release of the Notch intracellular domain. This fragment
of Notch enters the cell nucleus where it interacts with CSL tomodulate transcription (canonical Notch pathway). However, Notch-ligand interaction can also or alternatively activate
a non-canonical signalling pathway. Currently it is not clear whether this is an intrinsic property of the membrane-bound Notch receptor or whether Notch activated by its ligand,
requires additional unknown factors in order to transduce non-canonical signaling. Signaling through this pathway has been shown to block differentiation into myotubes [28,29],
peripheral nervous system development [30,111], neural crest development [112] and to promote axon growth and guidance [31]. Moreover, through a direct interaction with
IKKalpha Notch3 has been shown to be able to promote NF-KB activation in the T-cell [35].
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translocates to the nucleus, where it can bind the DNA-binding
protein CSL (also referred to as RBP-Jk and CBF-1 in mammals and
Suppressor of Hairless (Su(H) in Drosophila). In the absence of
NICD, CSL protein acts as a transcriptional repressor by binding
ubiquitous co-repressor proteins, such as silencing mediator of
retinoic and thyroid hormone receptors (SMRT) or Mint (also called
SHARP and Spen in human) [18]. The NICD generated upon ligand
binding compete with the repressor proteins and form a NICD/CSL
complex converting CSL from a repressor into an activator of
transcription. The NICD/CSL module is recognized by Mastermind
(MAM)/Lag-3 protein, and this complex is important to assemble
an active transcription complex on target promoters by recruiting a
positive regulator of transcription such as the ARC-L/MED mediator
complex [19], the histone ubiquitin Ligase, Bre-1 [20] and histone
acetyltransferases (HAT). This signaling module is referred com-
monly as the canonical effector of Notch signaling.
Components of the two families of basic helix-loop-helix tran-
scription factors, Hes and Herp (the latter also known as Hey, Hesr,
HRT, CHF and gridlock) have been identiﬁed as immediate transcrip-
tional targets [21].
In recent years, a detailed picture of the canonical Notch
pathway in ﬂies and vertebrates has emerged [22]. Central to this
pathway is, as mentioned above, the effector CSL. However, there is
accumulating evidence for aspects of Notch signaling that occur in a
CSL-independent manner. Although key genetic data in favor of a
non-canonical Notch signaling have been presented, the experi-
mental evidence for CSL-independent signaling is less direct, with
few biochemical elements identiﬁed up to date. Interestingly, PI3K
was identiﬁed as one intracellular mediator of Notch-dependent
anti-apoptotic activity [23]. Moreover, activation of AKT pathway
downstream of Notch signaling has been shown in differentiation
and neoplastic transformation of several tissues [24,25]. However,data from myogenic differentiation argue that Notch receptors that
have not undergone S1 cleavage, and hence no other cleavages, still
block myogenesis, and that Notch ICD constructs, lacking the CSL-
interacting domain, exert effects in blocking myogenesis [26–29].
Moreover, certain Drosophila Notch alleles, the mcd alleles, appear
to operate in a Deltex-dependent but Su(H)-independent manner
[30]. Furthermore, a recent report provides genetic and biochemical
evidence that Notch directs axon growth and guidance in Drosophila
via a non-canonical, signaling pathway, characterized by association
with the adaptor protein Disabled, and Trio, an accessory factor of
the Abl tyrosine kinase [31]. Interestingly, Disabled and Trio were
found associated with full-length Notch prior to cleavage, suggesting
the possibility that γ-secretase cleavage terminates the Notch/Abl
signal by separating the receptor-bound complex from membrane-
tethered components of the pathway such as Abl kinase and Rho
GTPases [31]. Moreover, deletion from Notch of the binding site for
Disabled impairs its action in axon patterning without disturbing
cell-fate control [31]. However, additional experiments will be
necessary to assess the various possible models. In light of this
possible molecular duality for the Notch signaling, it is important to
understand in detail how Notch exerts its action. It will be of great
interest to learn whether the context-sensitive and ﬂexible outputs
of Notch signaling in various cellular contexts reﬂect a balanced
contribution from both canonical and non-canonical Notch signaling
pathways. In addition, we could hypothesize that different Notch
receptors, possibly based on structural (i.e. presence or absence of
TAD domain) or functional differences (i.e. binding afﬁnity with
MAM; physical interaction with several components of the NF-kB
signaling pathway [32–35]), may have differential ability in
triggering canonical and non-canonical signaling pathways, thus
resulting in intersection and/or reciprocal control with each other.
This could justify the spatial and temporal differential expression of
several Notches during differentiation, as well as the apparently
491C. Talora et al. / Biochimica et Biophysica Acta 1782 (2008) 489–497opposite roles of Notch signaling in different cell compartments and
or functions (Fig. 1).
2. Notch and autoimmunity
The development of autoimmune diseases rises from the breakdown
of unresponsiveness to self antigens. ‘Central tolerance’ processes, via
clonal deletionof autoreactiveTcells in the thymus, are largelyeffective in
avoiding autoimmunity, but incomplete. Thus, mechanisms of ‘periph-
eral tolerance’ are essential to prevent harmful immune responses: the
active suppression of self-reactive T lymphocytes by a highly specialized
subpopulation of CD4+ T cells, known as CD4+CD25+FoxP3+ regulatory
T cells (Treg) [36], as well as the regulation of T effector functions, are
both directly implicated in the control of autoimmunity.
The role of Notch signaling in regulating thymocyte cell-fate
decisions is well established [37] and accumulating evidence indicates
that it is also involved in the differentiation of peripheral CD4+ T-cell
subsets, including TH1, TH2 and Treg [38]. Thus, an emerging and still
controversial role in autoimmunity has been recently suggested for
Notch receptors.
An important issue concerns a putative role of Notch signaling
activation in driving the generation and/or induction of T cells with
regulatory functions. Initially, it was shown that Notch signaling can
impose a regulatory phenotype on murine peripheral CD4+ T cells, by
their exposure to antigen presenting cells (APC), overexpressing the
human Jagged1 Notch ligand [39]. These ‘induced’ regulatory T cells
can inhibit primary and secondary immune responses and transfer
antigen-speciﬁc tolerance to recipient mice. Similar results were
obtained with human T cells, which were co-cultured with EBV-
positive human B-cell lines, engineered to overexpress human Jagged1
and used as APCs [40]. This treatment induces antigen-speciﬁc, IL-10-
producing regulatory T cells (in both CD4+ and CD8+ subsets), that
speciﬁcally inhibit the proliferative response and the cytotoxic-T-cell
activity to EBV proteins. These cells block the responses of fresh T
lymphocytes that have themselves never been exposed to a Notch
ligand, and importantly, spare responses to third-party stimulatory
cells. The same researcher group indeed, demonstrated that these cells
may be useful in the context of allogenic hematopoietic stem cell
transplantation, to avoid graft-versus-host disease (GVHD), while
preserving activity against tumoral or infective antigens [41].
Since then, different approaches revealed that Notch signalling can
be also involved in inﬂuencing the ‘naturally occurring’ subset of Treg.
Interestingly, expression of Notch transcriptional target, Deltex, in
naturally arising CD4+CD25+ regulatory T cells isolated from peripheral
blood of adult volunteers was signiﬁcantly higher when compared with
their CD4+CD25− counterparts [113], suggesting that Notch signaling is
active in these cells. Further, uponstimulation, the transcriptionofNotch
pathway components (such as, Notch4, Delta1 andHes1)was highly up-
regulated only in the CD4+CD25+ subset. These cells can thus exert
suppressive function by a cell-to-cell contact mechanism that may
involve Notch signaling between neighboring T cells.
Moreover, stimulation of naive CD4+ T cells with Delta1 involving
interactions with Notch3 promotes the differentiation toward the Th1
pathway [42], whereas Jagged1-mediated Notch1 activation is critical
in driving Th2 differentiation [43].Thus, the expression of multiple
Notch receptors and ligands in a range of different T cell types
indicates that Notch signaling pathway supports many of the
processes involved in the maintenance and function of different
mature T-cell populations. However, the precise role of Notch
signaling and the speciﬁc contribution of the different Notch receptors
and ligands is still controversial.
Recently, Notch3 receptor up-regulation was reported on natu-
rally occurring CD4+CD25+ regulatory T cells from spleens of wild-
type mice, when compared to the CD4+CD25− population [44].
Consistently, the analysis of lck-Notch3-IC transgenic mice revealed
a signiﬁcant increase in the generation and function of CD4+CD25+regulatory T cells. Interestingly, these mice failed to develop
streptozotocin-induced autoimmune diabetes, and the adoptive
transfer of lck-Notch3-IC transgenic CD4+ cells to immunocompetent
wild-type recipients prevents the progression of the disease [44].
The putative role of Notch3 in Treg biology has been also suggested
by demonstrating that the exposure of Treg to Jagged2-expressing
hematopoietic progenitor cells (HPC), selectively activates Notch3
signaling and directly drives the expansion of functional host-derived
Treg that halt autoimmune diabetes onset in NOD mice, the
spontaneous model of type 1 diabetes [45]. Intriguingly, the same
group reported an association between up-regulated expression of
Notch3 protein and enhanced FoxP3 expression in CD4+CD25+
regulatory T cells, following the treatment with Jagged2-overexpres-
sing hematopoietic progenitors.
However, despite the above ﬁndings, it should be noted that other
groups reported that the modulation of Notch signaling does not
always impact on thymic generation of naturally occurring Treg or
induction of regulatory T cells from naïve CD4+ T subset. In particular,
it has been recently reported that selective inhibition of Notch3 in
myelin-reactive T cells attenuates experimental autoimmune ence-
phalomyelitis (EAE) [46].
Furthermore, to date there is no report about any quantitative or
functional deﬁciency of regulatory T-cell subset in Notch knock-out
mouse models, perhaps because of the redundancy between different
receptors and ligands of the Notch family or the potential involvement
of non-canonical transductionpathways ofNotch signaling in regulatory
T-cell development.
Notably, the Notch signaling has also been linked to autoimmunity
because of its proposed and controversial function in driving
activation and differentiation towards TH1 fate of peripheral CD4+ T
cells (reviewed in [38]). Indeed, a dysregulated TH1 response may
perpetuate destructive inﬂammation and contribute to the pathogen-
esis of different human autoimmune diseases, such as multiple
sclerosis and rheumatoid arthritis [47,48]. This issue has been
extensively studied by several groups in the pathogenesis of EAE, a
mouse model of multiple sclerosis. Firstly, B. Osborne's group
demonstrated that Notch activation facilitates TH1 development by
directly promoting the transcription of T-bet, an essential factor for
TH1 differentiation [49]. They showed that blocking Notch signaling
by γ-secretase inhibitor (GSI) treatment in vitro or by expression of
Notch1 anti-sense construct in vivo, signiﬁcantly inhibits the expres-
sion of T-bet and the production of Interferonγ (IFN-γ) in TH1-
polarized CD4+ T cells. Furthermore, in vivo administration of GSI
signiﬁcantly attenuates the progression of TH1-mediated disease in
the EAE mouse model. Then, another group conﬁrmed the critical role
of Notch signaling in the control of peripheral T-cell functions, but
demonstrated that Jagged1 and Delta1 differentially regulate the
outcome of autoimmunity in the EAE model [50]. While Jagged1
signaling activation protected from EAE and increased the frequency
of IL-10-producing cells, the Delta1 activation worsened the EAE
disease and increased the frequency of IFN-γ-producing cells.
From another point of view, a loss of function mutation in the Itch
ubiquitin ligase, previously shown to be involved in Notch1 degrada-
tion [51], leads homozygous Itch−/− (itchy) mice to develop a fatal,
late-onset autoimmune-like disease [52]. Moreover, homozygous
itch−/−mice, carrying an activated Notch1 transgene, developed amore
severe autoimmune disease, supporting the assertion that Notch1 and
Itch mutations genetically interact [53]. Interestingly, the activation of
canonical Notch signaling does not correlate with the severity of the
observed autoimmune disease, suggesting that this phenotype may
arise from a non-canonical, CSL-independent mechanism.
Overall, the evidence collected so far, clearly shows that the Notch
signaling interferes with the generation and function of different T-
cell subsets (Fig. 2). However, the mechanisms underlying these
effects remain largely elusive and challenging. To this regard, the
heterogeneity of cellular outcomes is likely to arise from the complex
Fig. 2. Notch and autoimmunity. Schematic representation of the controversial role of Notch signaling in regulating autoimmunity. Several reports suggest that activation of Notch
signaling results in generation of both thymic-derived naturally occurring (nTreg) and peripherally-induced (iTreg) regulatory T cells, as well as IL-10-producing (CD4+IL-10+)
regulatory cells. However, other data report that inhibition of Notch signaling leads to the blockade of generation of TH1 lymphocytes, responsible of the development of
autoimmunity, thus suggesting a protection against autoimmunity.
492 C. Talora et al. / Biochimica et Biophysica Acta 1782 (2008) 489–497interactions between canonical and non-canonical Notch signaling,
possibly sustained by different ligand/receptor pairing and intersect-
ing extrinsic pathways.
3. Notch and lymphomagenesis: the cases of T and
B-cell malignancies
The oncogenic potential of Notch signaling was initially identiﬁed
by showing that a chromosomal alteration in a subset of T-cell
lymphoblastic leukemias/lymphomas containing a t(7;9)(q34;q34.3)Fig. 3. Notch signaling and T-cell leukemogenesis. The cartoon illustrates schematically the
would be able to sustain neoplastic transformation of bone marrow-derived HSC towards T-c
pre-TCR in thymocytes, would activate a number of oncogenic pathways, involved in the deve
in this way, through the interaction with pre-TCR, sustaining the maintenance and progresschromosomal translocation [54], resulted in the truncation of Notch1
transcript and the generation of a constitutively-active Notch1-ICD. In
subsequent studies, it appeared that b1% of all humanT-cell leukemias
or lymphomas contain this translocation [55]. However, aberrant
Notch signaling was subsequently found in several human T-cell
leukemias and lymphomas that lacked genomic rearrangements
[56,57], implying that up-regulated Notch signaling might have a
common role in human leukemogenesis (Fig. 3).
Accordingly, constitutively-active intracellular domains of Notch1
and 3 have been shown to cause T-cell Acute Lymphoblastic Leukemiadifferences between Notch1 and Notch3 in sustaining T-cell leukemogenesis. Notch1
ell leukemia, independently on pre-TCR. In contrast, Notch3, through relationships with
lopment of T-cell leukemia. The possibility that Notch1may directly activate Notch3 and
ion of T-cell leukemia, remains to be elucidated and is indicated by the question mark.
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andmurine T-ALL (reviewed in [58]). Furthermore, high levels of Notch3
were consistently expressed in samples of humanT-cell acute leukemias,
anddramatically reducedat clinical remission [59]. Interestingly, inT-ALL,
Notch3 is associated with the expression of its target gene, HES1, and of
the gene encoding pTα, important in pre-TCR signaling [59].
The molecular link between Notch and pre-TCR signaling
pathways assumes particular relevance taking into account that
combined expression of Notch3 and pTα has been reported in
virtually 100% of T-ALL patients examined [59], and that bone
marrow transplantation (BMT) with Notch1 overexpressing hema-
topoietic stem cells (HSCs) from mice lacking a functional pre-TCR,
failed to give rise to any T-cell transformation [60]. However, more
recent evidence suggests that Notch1 promotes transformation
through both pre-TCR-dependent and independent pathways
(reviewed in [58]). In particular, it was shown that Notch1-
dependent T-ALL is not essentially dependent on pre-TCR signalling,
but that pre-TCR signalling may facilitate the early onset of the
disease [61]. Indeed, the transient mimicking of pre-TCR signals (by
injection of anti-CD3ɛ antibodies), accelerates leukemia develop-
ment in BMT experiments with Notch1 overexpressing Rag2−/−
hematopoietic stem cells (HSCs). Intriguingly, Notch1 activation
causes transformation of Rag2−/− HSCs without any induction of pre-
TCR signaling, though with delayed kinetics. Furthermore, in this
system Notch1 constitutive activation signiﬁcantly up-regulates
expression of Notch3, previously shown to induce T-ALL in experi-
mental models [62]. Strikingly, Notch3 was reported as a Notch1
target also in human T-ALL cell lines [63,64]. These data argue that
high levels of Notch activity, possibly achieved through Notch1-
dependent overexpression of Notch3, could overcome the β-selection
checkpoint. In line with this idea, the absolute and pre-TCR-
independent requirement of Notch signaling to drive differentiation
of DN cells to DP stage, was recently demonstrated both in vitro and
in vivo [65,66], conﬁrming previous genetically-based observations
[59]. Moreover, von Boehmer's group recently proposed that thymic
precursors expressing various TCR complexes (pre-TCR, αβTCR or
γδTCR), may all induce differentiation of αβ CD4+CD8+ T cells, by
synergizing with Notch signaling of different intensity [67,68].
Interestingly, pre-TCR interacts more efﬁciently than the other two
receptors [67], thus requiring weaker Notch signaling to drive
precursors through the β-selection phase. Furthermore, a crucial role
for pre-TCR signaling has been demonstrated inmediating theNotch3-
dependent activation of a number of oncogenic transcription factors,
involved in the initiation and/or the progression of T-cell leukemia in
transgenic mice (i.e. NF-kB, Tal1, Ikaros) [35,69,70]. However, pre-TCR
signaling seems not to be a prerequisite for NF-kB activation triggered
byNotch receptors. Indeed, while Notch1 appears to be able to activate
NF-kB independently on the presence of pre-TCR [71], the presence of
pTα discriminates between canonical and alternative NF-kB pathway
activation, regulating either cell differentiation or proliferation/
leukemogenesis, in Notch3-IC transgenic mice [35].
Although the observations reported above do not deﬁnitely
establish a role for Notch1 signaling in promoting Notch3 expression,
there is the possibility that a combination of activated Notch1 and
Notch3 may be important in the development of T-cell leukemia.
In contrast to T-ALL, Notch1 mutations are not found in B-ALL
and activated Notch signaling is a potent inducer of growth arrest
and apoptosis in B-cell malignancies [72]. Indeed, it has been
shown that expression of constitutively-active, truncated forms of
the four mammalian Notch receptors inhibited growth and induced
apoptosis in both murine and human B-cell lines, but not T-cell
lines [72]. Similar results were obtained in human precursor B-cell
acute lymphoblastic leukemia cell lines when Notch activation was
achieved by co-culture with ﬁbroblasts expressing the Notch
ligands Jagged1 or Jagged2 [72]. Notably, all four truncated Notch
receptors, as well as the Jagged-mediated Notch activation, induceHes1 transcription and retroviral expression of Hes1 recapitulates
the Notch effects, suggesting that Hes1 is an important mediator of
Notch-induced growth arrest and apoptosis in B-cells [72].
It is however of note that overexpression of Notch2 is observed in
malignant cells from patients with B-cell chronic lymphocytic
leukemia (B-CLL), and is associated with increased B-cell survival
[73]. Moreover, it has been shown that oncogenic viral proteins utilize
the Notch signaling pathway to induce B-cell immortalization [74].
Altogether, it is tempting to speculate that corrupt Notch activation
plays opposite roles in different B-cell malignancies, acute or chronic,
possibly depending on the B-cell differentiation stage, at which the
main leukemogenic hit takes place.
In summary, activation of Notch signaling has different outcomes
underlying T versus B-cell malignancies, being always oncogenic in
T cell. In contrast, Notch appears to mediate growth arrest and
apoptosis in human precursor B-cell acute lymphoblastic leukemia
lines while it increases survival in B-CLL.
4. Notch signaling and skin: sustaining cell differentiation to stop
tumor growth
Notch activation has been mainly associated to its multiple
effects in sustaining oncogenesis, including the control of tumor
cell proliferation, migration, cell cycle progression, and inhibition of
apoptosis. Indeed, Notch signaling is constitutively activated in
several types of cancer cells and it is generally regarded as an anti-
apoptotic and pro-oncogenic signal. The most studied and well-
established function of Notch signaling in promoting oncogenesis is
the ability (i) to induce growth-promoting genes such as cyclin D1
and c-myc and (ii) to trigger anti-apoptotic pathways such as
PI3-Kinase/AKT. Moreover, several data indicate that in tissues in
which Notch exhibits growth-promoting functions, it acts as a
critical mediator of self-renewal and stem cell maintenance. In
contrast, in normal epidermis, Notch1, Notch2 and Notch3 are all
expressed suprabasally, indicating that their physiological role is
mostly associated with keratinocyte differentiation. For example,
blockade of Notch1 predisposes murine skin to basal cell
carcinoma-like tumors. This observation could be explained by
the fact that in normal keratinocytes, Notch activation induces cell
cycle arrest [75]. Many hypotheses have been put forward to
explain this dual activity. The emerging conclusion is that the ﬁnal
outcome of Notch activation depends on the cell type, the stimulus,
and the context of activation.
Hence, although initially it appeared counter-intuitive that the same
signaling cascade mediates different outcomes, consideration gathered
from other cellular systems indicates that the archetypal model in
which Notch signaling activation can serve in stem cell maintenance
and inhibition of cellular differentiation, might be re-evaluated.
Notch signaling can indeed play different roles based on cellular
context as well as on differential involvement of different Notch
receptors. Notch1 receptor activation can inhibit the growth of
hepatocellular carcinoma, small-cell lung cancer, and prostate cancer
cells [76–81]. Although this growth inhibitory role of Notch has mainly
been suggested on the basis of constitutively-active Notch1-IC over-
expression studies, data generated by inactivation of endogenous
Notch signaling further support the notion that Notch has tumor-
suppressive functions in prostate cancer cells [80]. Furthermore,
Notch1 deﬁciency in the liver results in the spontaneous proliferation
of Notch1−/− hepatocytes. Although Notch1 deﬁciency in the liver did
not result in the development of liver carcinomas, this observation
together with the ability of Notch1 overexpression to inhibit hepatocel-
lular carcinoma cell proliferation support the hypothesis that Notch1
signaling may be part of a tumor-suppressor program in the liver [82].
Conversely, Notch3 overexpression has been reported to be
responsible for increased in vitro tumor cell growth in human lung
cancer and Notch3 constitutive activation was reported to inhibit
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increased expression of Notch3 has been observed in spontaneous
human pancrea tumors [84] and in T-ALL [59]. Overall, the above
observations support the notion that in addition to maintaining
precursor cells, Notch signaling also participates in the induction of
terminal differentiation and growth arrest.
4.1. Notch in keratinocyte differentiation
Inmouse skin theNotch pathway is essential for the normal growth
control of the epidermis and in the maintenance of the normal border
between basal and upper differentiating layers [85]. Notch1 deletion in
the epidermis results in increased cell proliferation, thus reﬂecting the
growth inhibitory effects exerted by activated Notch1 in primary
keratinocytes in culture [85]. This is consistent with the ﬁnding that
p21WAF1/Cip1 expression can be induced by activated Notch1
expression [85]. Consistently with the model that the Notch pathway
plays an important role in regulating epidermal homeostasis, Notch1
deﬁciency in the epidermis results in a pleiotropic phenotype, with
hair loss, hyperproliferation, deregulated expression of multiple
differentiation markers and spontaneous basal cell carcinomas
[85–87]. Thus, consideration gathered from human and mouse
epidermis indicates a simple model in which Notch signaling
activation regulates epidermis homeostasis by ﬁrst promoting stem
cell-transit amplifying cell transition and thereafter inducing a
differentiation-associated growth arrest.
However, even this apparently simple model can exhibit
complicated dynamics, generated not only by cross-talk between
Notch and other signaling molecules but also by an additional
complexity, intrinsic to the Notch signaling. There is growing
evidence that signals transmitted through Delta or Jagged ligands
can differentially affect the target cell [88]. Analyses using
keratinocytes from human and mouse skin indicate that multiple
Notch receptors and ligands are expressed in keratinocytes. In
human epidermis, it has been proposed that high expression of Dll1
by clusters of stem cells protects them from undergoing terminal
differentiation, while stimulating neighboring cells to become
transit amplifying cells [89,90] and other observations indicate
that Dll1 expression also has cell-autonomous effects [91,92].
Additionally, different ligands mediate different effects, not only in
vivo [93], but also in culture, where loss of Jagged1 or Dll1 has
different effects on the expression of integrins and spinous layer
markers. Such differences are likely to reﬂect not only the different
cell populations that express the ligands, but also the ability of the
same cell population to respond differently to Dll1 and Jagged1 [94].
In vitro studies have suggested that NICD1 overexpression
promotes keratinocyte differentiation, including some spinous layer
genes such as K1, through a mechanism which appeared to be
independent of RBP-Jk, thus suggestive of a non-canonical Notch
signaling pathway [75]. However, more recent studies in vivo have
indicated that loss of canonical Notch signaling by conditional loss of
RBP-Jk, rather than promoting proliferation, resulted in a marked
thinning of embryonic epidermis and by a marked decrease in
proliferation within the RBP-Jk deﬁcient epidermis [91]. According to
these data, in vivo, the spinous fate induced by Notch is dependent on
the canonical RBP-J-dependent-pathway. Thus, it has been suggested
that it could be formerly possible that Notch1 functions as a tumor
suppressor through a non-canonical pathway or as an alternative
possibility perturbations in canonical Notch signaling compromise
epidermal barrier function, which in turn leads to hyperproliferation
as an indirect secondary reaction [92]. However, blockade of Notch1
but not loss of RBP-Jk predisposes murine skin to basal cell carcinoma-
like tumors. This observation simply indicates that removing one
member of the Notch family, namely Notch1, does not have equal
effects with the removal of RBP-J. Thus, a complex possibility is that
loss of either RBP-Jk or Notch1 differently affects both balance andstrength of Notch canonical and non-canonical pathways during
keratinocyte differentiation. In this model, keratinocytes can normally
differentiate in the presence of a strong signaling through the RBP-Jk,
whereas the synergism between the non-canonical and canonical
signaling restricts the growth potential of differentiating keratino-
cyte. In the absence of RBP-Jk, the balance between canonical and
non-canonical Notch signaling is shifted towards the non-canonical
one, which might be important to actively repress expression of
differentiation markers. Notably, among the Notch family members,
Notch1 elicits the strongest transcriptional activation on promoters
whose activation is dependent on RBP-Jk-dependent canonical Notch
signaling [95]. Similarly, we could hypothesize that Notch1, elicits the
strongest activation of non-canonical signaling in keratinocytes.
Thus, loss of Notch-1 activity does not inﬂuence signiﬁcantly the
balance between canonical and non-canonical Notch signaling, but
instead strongly decreases the strength of both canonical and non-
canonical signaling required to restrict the growth potential of a
differentiating keratinocyte.
A complex picture of keratinocyte differentiation emerges from
these considerations, including the involvement of non-canonical
Notch signal strength. Further studies are required to fully elucidate
the mechanism underlying this process.
4.2. Notch in skin cancer
Tissue-speciﬁc conditional ablation of Notch1 under the control of
the keratin-5 promoter in the basal layer of murine epidermis results
in early hyperplasia followed by the spontaneous development of
basal cell carcinoma (BCC)-like tumors [87]. In this context of Notch1
deﬁciency, the Wnt pathway was derepressed and beta-catenin-
mediated signaling was re-activated, resulting in tumorigenesis.
Previous studies also pointed to a tumor-suppressive role for
Notch signaling in mouse skin. In a presenilin-deﬁcient mouse
model, loss of presenilin, a component of gamma-secretase complex,
results in epidermal hyperplasia and the development of keratino-
cyte-derived skin cancers [96]. In presenilin-deﬁcient mice, beta-
catenin signaling was also up-regulated and the downstream target
cyclin D1 was activated. Thus, the interruption of Notch1 signaling in
murine skin via two independent approaches, direct targeting of the
gene or inhibition of cleavage of the encoded protein, produces
similar consequences and highlights the importance of Notch-
mediated regulation of beta-catenin signaling in murine keratino-
cytes. In a recent report it has been shown that the pan-inhibition of
canonical Notch signaling by dominant negative (DN)MAML1 results
in the spontaneous formation of cutaneous squamous cell carcinoma
(SCC) [97]. Moreover, DNMAML1 expressing mice have accumulation
of nuclear beta-catenin and up-regulation of cyclin D1 gene
expression [97]. These observations suggest that Notch signaling
may play a critical role in the pathogenesis of both BCC and SCC,
originating from epidermal cells that exhibit profoundly different
clinical manifestations. Consequently, understanding how selective
inhibition of Notch1 in the skin gives rise to BCC while pan-inhibition
of canonical Notch signaling in the skin gives rise to de novo
development of SCC could provide important information in order to
identify the mechanisms that govern the behavior of Notch signaling
in both skin differentiation and cancer. The cytostatic and differ-
entiative effects of Notch signaling are barriers to tumor emergence
and progression. Thus, the simplest hypothesis could be that loss of
canonical Notch signaling represents a mechanism for evasion of
Notch growth inhibition potential. Alternatively, since the non-
canonical Notch signaling remains intact, as a consequence of the
inhibition of canonical Notch signaling, only a speciﬁc subset of genes
may be activated and/or repressed (i.e. genes involved in anti-
apoptotic pathways, such as PI3K [23]). Thus, the balance between
non-canonical and canonical Notch signaling determines the correct
unfolding of the keratinocyte differentiation process.
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HPV infection plays a critical role in cervical cancer, through the
expression of the viral proteins E6/7 which are able to inactivate p53
and Rb-dependent tumor-suppressor pathways. Several reports are
consistent with the view that Notch signaling plays a role in the
development of cervical cancer [98–100]. However, it was shown that
Notch1 expression is down-regulated in late stage HPV-induced
tumors, and that Notch signals counteract the HPV-induced neoplastic
transformation by promoting E6 and E7 down-modulation [101].
Immunohistochemical data have indicated that Notch1 expression is
elevated in squamous metaplasia of the columnar epithelium and in
early HPV-induced lesions (CINI–III), as well as in differentiated
superﬁcial carcinomas of the cervix [98]. Conversely, Notch1 expres-
sion is substantially reduced in invasive cervical cancers [101]. From
this controversy could arise two conclusions: ﬁrstly, the dual pattern
of Notch1 expression reveals a dual function of Notch signaling,
depending on the cell biology context: namely, early stage versus later
stage of cervical carcinogenesis. Secondly, the functional interaction
between Notch and other signaling molecules determines a qualita-
tively different Notch signaling, sensed and interpreted differentially
by the cells and resulting in a different outcome. Interestingly, it has
been shown that E6 binds human MAML1, the transcriptional co-
activator of Notch receptors, perhaps preventing MAML1 from
amplifying Notch signaling and activating target genes [76,102].
Interestingly, the promoter activity of the HES-1 gene, which is
classically used to measure endogenous Notch1/RBP-Jk activity, is
increased in HPV-negative cervical cancer cell lines, when compared
to HPV-positive cells (Talora et al. unpublished observation). Thus, it
suggests that HPV infection actively promotes down-modulation of
Notch signaling. Consistent with this observation, it has been recently
reported that the Notch1 gene is a target of p53 and can be down-
regulated by E6 through p53 degradation in normal human epithelial
cells [103]. Therefore, hypo-activity of Notch1 signaling may serve to
counteract Notch1mediated-repression of E6 and E7 expression [101].
Paradoxically, a synergic role of Notch1 with E6/E7 in the protection of
HaCat epidermal cells, against apoptotic stimuli has also been
reported [75]. However, full ablation of Notch activity by DN-RBP-Jk
somewhat boosts proliferation of cervical cancer cells, but this takes
place at the expense of an increased susceptibility to pro-apoptotic
stimuli [104], likely reﬂecting a dual role of Notch1 in the biology of
cervical cancer cells. A model that may integrate these ﬁndings is as
follows. HPV cancer cells can translate a low dose of Notch1 signals
into an anti-apoptotic response. The cell cycle machinery of cervical
cancer cells, on the other hand, would ﬁlter this level of Notch1
activity as noise and therefore implement a growth arrest program
only at a higher level on Notch1 activity. In the normal epithelium of
the cervix only Notch1 and Notch2 are expressed [101]. Interestingly,
overexpression of Notch1, Notch2 and Notch3 resulted in a marked
decrease of cervical cancer cell proliferation (Talora et al., unpublished
observation). In contrast only Notch1 but not Notch2 results down-
modulated in cervical cancer cells and primary tumors [101,103].
Notably, among the Notch family members, Notch1 elicited the
strongest transcriptional activation on promoters whose activation is
dependent on canonical Notch signaling [95]. Hence, we could
hypothesize that enforced overexpression of either Notch1, 2 or 3
elicits Notch signaling, whose strength is able to overcome the active
HPV-mediated repression of canonical Notch signaling. However, at
physiological levels of expression, only Notch1, with its strongest
activation of canonical Notch signaling, has the ability to counteract
HPV activity. Thus, an attractive hypothesis could be that HPV
adopts a selective strategy for the evasion of the antiproliferative
function of the canonical Notch signaling generated by Notch1, as
this capacity enables the corrupt use of the non-canonical Notch
pathway in tumor progression.6. Conclusion and perspectives
Over the last several years, a great deal of progress has been made
in our understanding of the signal transduction pathways that
mediate the various cellular responses to Notch signaling. The
realization that Notch's family members can execute different
functions and may be distinctly regulated has further increased the
complexity of Notch signaling. For instance, Notch2, but not Notch1, is
required for proximal fate acquisition in the mammalian nephron
[105]. Moreover, Notch2 cannot compensate for the loss of Notch1
function during T-cell maturation [106]. Finally, Notch3 but not
Notch1 seems to be able to sustain Ikaros alternative splicing in the
experimental model of T-ALL [70]. Thus, these results establish
distinct and non-redundant roles for Notch receptors. In addition,
Delta and Jagged can evoke different responses. In T cells, for example,
it has been suggested that these different ligands preferentially
activate different Notch receptors [43,88]. However, despite the
conceptual appeal of differential Notch usage by Jagged or Delta, an
alternative possibility is a differential signaling through the same
Notch receptor paired with different ligands. Indeed, in Drosophila
only a single Notch gene is expressed, thus the response to different
ligands may involve signaling differences [107–109].
Certainly, different Notch family members seem to have distinct
preferences for transcriptional regulatory elements [95], which could
lead to distinct effects on proliferation and differentiation. Differences
may therefore lie in other pathways activated by Notch, perhaps not
involving RBP-Jk. However, the mechanisms regulating non-canonical
pathways also require additional elucidation. Of primary interest is the
relationship between intracellular versus membrane-bound forms of
the Notch receptors, which could lead to distinct effects of Notch
signaling. As an example, recent data indicate that Notch3 is involved
in vascular injury and has an important role in the cerebral autosomal
dominant arteriopathy with subcortical infarcts and leukoencephalo-
pathy (CADASIL) pathology but its exact function is unknown, as yet.
Investigation of CADASIL mutant Notch3 shows that the majority of
mutations do not change CBF1/RBP-Jkappa-mediated canonical Notch
pathway activation, so that the pathological consequences of Notch3
mutations in CADASIL patients cannot be simply explained by loss- or
gain-of-function in the classic Notch signalling pathway. This suggests
that a novel Notch3-mediated signalling pathway may be present in
Vascular Smooth Muscle Cells [110].
In summary, the current model of the Notch pathway leads to a
number of challenging questions: the answers are likely to reveal the
mechanisms underlying critical cellular responses, and hopefully will
lead to the development ofmore effective therapeutics for a number of
human diseases.
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